Patent · US Active

Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof

US8815933B2 · kind B2 · utility

2Cited by

57References

13Claims

0Family size

Assignee

Forum Pharmaceuticals, Inc. · US

Inventors

Richard Chesworth · Boston, US
Gideon Shapiro · Gainesville, US
Gerhard Koenig · Newton, US

Key dates

Filing date	Feb 7, 2014
Grant date	Aug 26, 2014
Priority date	—
Expiry date	Feb 7, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.